The preferred protocol in the neoadjuvant treatment of HER2-positive breast cancer is the combination of pertuzumab + trastuzumab with chemotherapy (Table 2), based on the results of the NeoSphere and TRYPHAENA clinical trials, which showed that the administration of dual blockade of trastuzumab + pertuzumab with chemotherapy in neoadjuvant setting significantly increased the rate of pathologic complete response (pCR) compared to the administration of a single anti-HER2 drug with chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.